CombinatoRx's "Sophie's choice" situation with a pair of Phase II drugs may get resolved not by the cash-lean company but by a partner, and the question could depend on how spooked are investors by the calamity that ensued from NitroMed's attempt to grab market share with a drug that pairs two generics.